This article was originally published in The Rose Sheet
Novartis Consumer Health appointed Clearasil distributor in U.S. and Canada, effective July 2, to strengthen position of skin care brand, UK firm announces. Former Clearasil marketer Procter & Gamble will distribute brand until July 1 and will continue to manufacture it in North America until further notice, Boots says. Novartis and Boots will work together to evaluate opportunities for Clearasil, including product revamp and possibility of bringing other Boots products in development to U.S., firm says. Boots purchased Clearasil for $340 mil. last fall in effort to gain access to U.S. OTC market (1"The Rose Sheet" Oct. 23, 2000, p. 3)
You may also be interested in...
Boots Healthcare International views its acquisition of the Clearasil acne prevention and treatment brand as a possible springboard for creating an OTC drug marketing presence in the U.S.
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle